Skip to main content
. 2020 May 9;21(9):3349. doi: 10.3390/ijms21093349

Figure 1.

Figure 1

Effects of multiple kinase inhibitors on the Huh7 cell viability cells (n = 3), (A) sorafenib; (B) regorafenib; (C) lenvatinib. Huh7 cells were treated with sorafenib, regorafenib or lenvatinib at 0, 1, 2, 5, 10, or 20 μM for 48 h. Cell viability was measured by MTS assay. * p < 0.05, compared to Huh7 treated without multiple kinase inhibitors. Pictures taken by phase contrast microscopy (×20): (D) Huh7 control; (E) Huh7 cells treated with 2 μM regorafenib; (F) 20 μM regorafenib; (G) 2 μM lenvatinib; (H) 20 μM lenvatinib.